About admin

This author has not yet filled in any details.
So far admin has created 41 blog entries.

Dr hab. n. med. Jakub Dobruch, FEBU – Liquid Biopsy

Dr hab. n. med. Jakub Dobruch, FEBU. Urological Review, The Polish Association of Urology bimonthly magazine. No. 5/2016

Liquid Biopsy is an example of a new kind of research that could revolutionize cancer detection and treatment of patients affected.

By | November 14th, 2016|Medical publications|0 Comments

Blood test could identify aggressive prostate cancer

The Times

The Times: thousands of men with prostate cancer could be saved from unnecessary operations thanks to a blood test...

By | November 8th, 2016|Chronix news|0 Comments

Advanced Cancer Diagnostics Showcasingat 2016 NCRI Cancer Conference 6-9 November 2016

Chronix Biomedical’s Ireland & UK distributors Advanced Cancer Diagnostics will be attending and showcasing the latest Chronix diagnostic tests: Second Opinion Prostate Cancer Evaluation Test Second Opinion Breast Cancer Evaluation Test Delta Dot Treatment Monitoring Test CNI Cancer Evaluation Test Please visit our booth #79 at The BT Convention Centre, Kings Dock, Waterfront, Liverpool L3 [...]

By | November 3rd, 2016|Events|0 Comments

ASCO 2016

“Tumor cell-free DNA copy number instability (CNI) predicts therapeutic response to immunotherapy prior to cycle 2” , was presented at the American Society of Clinical Oncology (‘ASCO’) Annual Meeting 2016 on 5 June 2016 at McCormick Place in Chicago, Illinois. The abstract and poster presentation describe the work conducted by independent oncologists in a blinded [...]

By | November 3rd, 2016|Events|0 Comments

Chronix Biomedical updates on progress with prostate and pancreatic cancer validation studies

Chronix Biomedical

Chronix Biomedical, Inc., a developer of novel cancer blood-based molecular diagnostics, is pleased to update investors on the progress of two clinical studies...

By | November 3rd, 2016|Chronix news|0 Comments

Experts from Chronix Biomedical about the CNI Tests – Innovative Cancer Diagnostics

#TheTurningPointInCancerFight

By | November 3rd, 2016|Video|0 Comments

Prof. Piotr Radziszewski – New generation oncological biomarkers – focusing on Chronix company

Prof. Piotr Radziszewski. New generation oncological biomarkers – focusing on Chronix company. 1.10.2016.

We present a lecture delivered at the 5th Polish women and men health debate according to Medical guidelines – kidney cancer, bladder cancer.

By | November 3rd, 2016|Medical publications, Video|0 Comments

First published results in breast cancer

Beck J, Urnovitz HB, Mitchell WM, Schütz E. Next generation sequencing of serum circulating nucleic acids from patients with invasive ductal breast cancer reveals differences to healthy and nonmalignant controls. Mol Cancer Res 2010; 8:335-42.

Chronix has first used the NGS technology for investigation into the use in breast cancer with very promising results.

By | November 3rd, 2016|Medical publications|0 Comments

Defining variances in healthy

Schütz E, Akbari MR, Beck J, Urnovitz H, Zhang WW, Bornemann-Kolatzki K, et al. Chromosomal instability in cell-free DNA is a serum biomarker for prostate cancer. Clin Chem 2015;61:239-48.

In order to discriminate between normal interindividual variabilities and traces from cancer, the situation in healthy individuals is of critical knowledge.

By | November 3rd, 2016|Medical publications|0 Comments

Predicting Treatment Outcomes in Immunotherapy

Weiss, G. et al. Tumor cell-free DNA copy number instability (CNI) to predict therapeutic response to immunotherapy prior to cycle 2. J ClinOncol 34, 2016 (suppl; abstr 3027).

We measured CNAs changes during treatment by computing a genomic copy number instability index (CNI) of cfDNA and Treg-specific demethylation region (TSDR) as measure for Tregs% of leukocytes compared to response.

By | November 3rd, 2016|Medical publications|0 Comments